Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team
Department of Pediatrics; Program in Molecular Medicine
Adult; Anti-HIV Agents; Cohort Studies; Female; Follow-Up Studies; HIV Infections; *HIV-1; Humans; Infant; Infant, Newborn; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; effects
Immunology and Infectious Disease | Pediatrics
The safety, toxicity, and pharmacokinetics of intrapartum and early newborn nevirapine were evaluated in 17 human immunodeficiency virus type 1-infected women in labor and their newborns. No adverse effects of nevirapine were noted in any study mothers or infants. Following maternal dosing with 200 mg during labor, concentrations exceeding 100 ng/mL (10 times the in vitro IC50) were achieved in the newborns. Nevirapine elimination was prolonged in both mothers and infants, with median half-lives ranging from 36.8 to 65.7 h. Administration of 200 mg orally to the mothers in labor and of a single 2-mg/kg oral dose to the infants at 48-72 h after birth maintained serum concentrations in the infants > 100 ng/mL through 7 days of life.
J Infect Dis. 1998 Aug;178(2):368-74.
The Journal of infectious diseases
Mirochnick M, Fenton T, Gagnier P, Pav JW, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL. (1998). Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. Immunology/Infectious Disease. Retrieved from https://escholarship.umassmed.edu/peds_immunology/2